ESPR | Esperion Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.4500 - 2.5400
52 Week Range	1.1600 - 3.40
Beta	1.09
Implied Volatility	94.68%
IV Rank	5.91%
Day's Volume	2,619,185
Average Volume	3,780,120
Shares Outstanding	197,035,000
Market Cap	496,528,200
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2013-06-26

Valuation
Profitability
Growth
Health
P/E Ratio	-3.76
Forward P/E Ratio	N/A
EPS	-0.67
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	240
Country	USA
Website	ESPR

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

ESPR's peers: ASRT, AYTU, ELAN, SIGA, INVVY, CTLT, EGRX, ANIP, PAHC, DCPH, PBH, COLL, PCRX, ITCI, ALKS, NBIX, IRWD, AVDL, LFCR, RMTI, KMDA, AGRX, TAK, HLN

*Chart delayed

Analyzing fundamentals for ESPR we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is very poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see ESPR Fundamentals page.

Watching at ESPR technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on ESPR Technicals page.